Alemtuzumab remains in the news

Sanofi pulls Campath to clear way for higher-priced Lemtrada
Genzyme has been developing Campath-slash-Lemtrada for MS, hoping to become a big player in that disease area. But MS drugs such as Biogen Idec's ($BIIB) Tysabri and Novartis' ($NVS) Gilenya have price tags much higher than Campath's, at least at ...
See all stories on this topic »

Sanofi withdraws Campath in US and EU
Pharma Times
French drugmaker Sanofi's Genzyme unit is pulling its cancer drug Campath/MabCampath from markets on both sides of the Atlantic in order to optimise the pending launch of the drug as a treatment for multiple sclerosis, according to reports. The company ...
See all stories on this topic »

Genzyme Avoids Marketing Misstep by Pulling Drug Used - FDA News
Apparently assured of U.S. and EU approval for Lemtrada in relapsing multiple sclerosis (MS), Genzyme is pulling its leukemia drug Campath, which has the ...

CoI: multiple